Abbott Laboratories Corporation

Karo Bio Ab

Tom W Von Geldern

James T Link

Philip R Kym

Gang Liu

Martin Winn

Zhili Xin

Zhonghua Pei

Russell Drew Cink

Chunqiu Lai

Marvin Robert Leanna

Noah Tu

Richard D Bishop

Bradley D Gates

Lars Hagberg

Steven J Richards

Peer B Jacobsen

John K Pratt

Steven Armen Boyd

Gui-Dong Zhu

Hwan-soo Jae

Indrani W Gunawardana

Sheldon Wang

John K Lynch

Michael A Staeger

Jennifer C Freeman

Benjamin C Lane

This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.

Glucocorticoid receptor ligands for the treatment of metabolic disorders

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Glucocorticoid receptor antagonists for treatment of diabetes

Growing community of inventors

Richmond, IL, United States of America

Tom W Von Geldern